Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor: (hereinafter referred to as Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.
1. A method of treating a subject suffering from or having an increased risk for cardiovascular diseases, the method comprising administering to said subject in need thereof an effective dosage amount of a compound of the formula A:
or a pharmaceutically acceptable salt thereof, wherein the effective dosage amount of said Compound A to be administered to said subject is 1 mg, 2.5 mg, 5 mg, 10 mg, or 25 mg daily, wherein said daily administration decreases LDL-C concentrations in a dose-dependent manner with maximum decreases from baseline of approximately 40% to 53% following said 1 mg, 2.5 mg, 5 mg, 10 mg, or 25 mg of said daily administration of compound A or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein said effective dosage amount of said compound A to be administered to the subject in need thereof is 5 mg or 10 mg daily.
3. The method according to claim 1 , wherein the effective dosage amount of said compound A to be administered to the subject in need thereof is 5 mg daily.
4. The method according to claim 1 , wherein the effective dosage amount of said compound A to be administered to the subject in need thereof is 10 mg daily.
5. The method according to claim 1 , wherein said compound A is to be administered to the subject in need thereof for 1, 5, 10, 20, 40, 52, 100, or 200 weeks.
6. The method according to claim 1 , wherein said compound A is to be administered to the subject in need thereof for at least one week or at least three weeks.
7. The method according to claim 1 , wherein said cardiovascular diseases are selected from hyperlipidemia or mixed dyslipidemia.
8. The method according to claim 2 , wherein said effective dosage amount of said compound A to be administered to the subject in need thereof is 5 mg or 10 mg daily in a solid oral dosage form or liquid oral dosage form.
9. The method according to claim 8 , wherein said solid oral dosage form is a tablet.
10. The method according to claim 8 , wherein said solid oral dosage form is a capsule.